Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIS649 multiple-dose study in IgA nephropathy
2019-002531-29Phase 2Unknown
- Sponsor
- Visterra
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sibeprenlimab in IgA nephropathy (IgAN) (4 arms), sponsored by Visterra. Primary endpoint: Primary safety objectives and parameters. Status: unknown.
02
Drugs
sibeprenlimab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2019-002531-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002531-29.